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BACKGROUND
Patients with atherosclerotic vascular disease remain at high risk for cardiovascu-
lar events despite effective statin-based treatment of low-density lipoprotein (LDL) 
cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by 
anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein 
(HDL) cholesterol levels. However, trials of other CETP inhibitors have shown 
neutral or adverse effects on cardiovascular outcomes.
METHODS
We conducted a randomized, double-blind, placebo-controlled trial involving 
30,449 adults with atherosclerotic vascular disease who were receiving intensive 
atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deci-
liter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter 
(2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter 
(1.03 mmol per liter). The patients were assigned to receive either 100 mg of ana-
cetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The 
primary outcome was the first major coronary event, a composite of coronary death, 
myocardial infarction, or coronary revascularization.
RESULTS
During the median follow-up period of 4.1 years, the primary outcome occurred 
in significantly fewer patients in the anacetrapib group than in the placebo group 
(1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 
95% confidence interval, 0.85 to 0.97; P = 0.004). The relative difference in risk was 
similar across multiple prespecified subgroups. At the trial midpoint, the mean 
level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in 
the anacetrapib group than in the placebo group (a relative difference of 104%), 
and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 
mmol per liter), a relative difference of −18%. There were no significant between-
group differences in the risk of death, cancer, or other serious adverse events.
CONCLUSIONS
Among patients with atherosclerotic vascular disease who were receiving intensive 
statin therapy, the use of anacetrapib resulted in a lower incidence of major coro-
nary events than the use of placebo. (Funded by Merck and others; Current Con-
trolled Trials number, ISRCTN48678192; ClinicalTrials.gov number, NCT01252953; 
and EudraCT number, 2010-023467-18.)
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Evidence from large-scale, random-ized trials has shown that each reduction of 40 mg per deciliter (1 mmol per liter) in 
the level of low-density lipoprotein (LDL) choles-
terol reduces the risk of coronary events (includ-
ing coronary death, myocardial infarction, and 
revascularization procedures) and ischemic stroke 
by approximately one quarter during each year 
after the first year of administration (when the 
effect is smaller).1 Moreover, further reductions in 
LDL cholesterol levels have been shown to produce 
additional reductions in cardiovascular risk.2-4 Nev-
ertheless, these risks remain high among persons 
with atherosclerotic vascular disease.3-5 Although 
higher levels of high-density lipoprotein (HDL) 
cholesterol are associated with a lower risk of 
vascular events, previous trials have not shown 
that raising HDL cholesterol levels reduces risk.5,6
Cholesteryl ester transfer protein (CETP) fa-
cilitates the exchange of cholesteryl esters and 
triglycerides between HDL particles and athero-
genic particles containing apolipoprotein B in 
the blood.7 Pharmacologic inhibition of CETP can 
produce substantial increases in HDL cholesterol 
levels, along with reductions in levels of non-HDL 
cholesterol (particularly LDL cholesterol). How-
ever, previous randomized clinical outcomes trials 
of CETP inhibitor therapy were stopped after ap-
proximately 2 years of follow-up because of either 
hazards associated with the therapy or an appar-
ent lack of efficacy.8-10
Anacetrapib is a potent CETP inhibitor that 
has been found to have an acceptable side-effect 
profile in previous, smaller studies.11,12 Here, we 
report the findings of the phase 3 Randomized 
Evaluation of the Effects of Anacetrapib through 
Lipid Modification (REVEAL) trial, which as-
sessed the clinical efficacy and safety of anacetra-
pib (at a dose of 100 mg once daily) for approxi-
mately 4 years among more than 30,000 patients 
with preexisting atherosclerotic vascular disease 
who were receiving effective statin therapy.13
Me thods
Trial Organization and Oversight
The trial was designed and conducted by indepen-
dent investigators (supported by the British Heart 
Foundation and Medical Research Council) in 
the Clinical Trial Service Unit at the University of 
Oxford (the regulatory trial sponsor), Oxford, 
United Kingdom, in collaboration with the Throm-
bolysis in Myocardial Infarction (TIMI) Study 
Group at Brigham and Women’s Hospital and 
Harvard Medical School in Boston, along with 
other members of the steering committee and 
Merck. Merck also funded the trial and provided 
the trial drugs. The trial protocol, available with 
the full text of this article at NEJM.org, was ap-
proved by all the relevant institutional review 
boards and regulatory authorities. The trial de-
sign, methods, and recruitment activities, which 
build on those of previous Heart Protection Study 
(HPS) trials conducted by the Clinical Trial Ser-
vice Unit at the University of Oxford, have been 
reported previously.13
The manuscript was prepared by the writing 
committee and was then reviewed and approved 
by all voting members of the steering committee. 
Merck provided comments on the draft manu-
script but otherwise had no role in the prepara-
tion of the manuscript or in the decision to sub-
mit it for publication. The first and last members 
of the writing committee vouch for the complete-
ness and accuracy of the data and for the fidelity 
of the trial to the protocol.
Patients
Men and women who were older than 50 years 
of age were considered to be eligible if they had 
a history of myocardial infarction, cerebrovascular 
atherosclerotic disease, peripheral-artery disease, 
or diabetes with symptomatic coronary heart dis-
ease. Key exclusion criteria were an acute coronary 
event or stroke less than 3 months before random-
ization; a planned coronary revascularization pro-
cedure; clinically significant liver, kidney, inflam-
matory muscle, or other disease; current treatment 
with a fibrate, niacin, or any drug contraindicated 
with anacetrapib or atorvastatin; a previous ad-
verse reaction to a statin; and known poor ad-
herence to clinic visits or medication.13 All the 
patients provided written informed consent.
Trial Procedures
All eligible patients entered a prerandomization 
run-in phase in which atorvastatin was adminis-
tered with the intention of reducing the LDL 
cholesterol level to below 77 mg per deciliter 
(2.0 mmol per liter).13 After 8 to 12 weeks, pa-
tients were excluded if they no longer met the 
eligibility criteria, had not adhered to the atorva-
statin regimen, or had a total cholesterol level of 
more than 155 mg per deciliter (4.0 mmol per 
The New England Journal of Medicine 
Downloaded from nejm.org at QUEEN MARY AND WESTFIELD COLLEGES on June 14, 2019. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
n engl j med 377;13 nejm.org September 28, 2017 1219
Anacetr apib in Atherosclerotic Vascular Disease
liter), as measured by means of a desktop chem-
ical assay (Reflotron Plus, Roche Diagnostics). 
Eligible patients were then assigned with the use 
of minimized randomization14 to receive 100 mg 
of anacetrapib once daily or matching placebo in 
addition to the atorvastatin regimen.
Routine follow-up visits were scheduled at 
2 and 6 months after randomization, and then 
every 6 months until the end of the trial. All 
serious adverse events (including potential trial 
outcomes), nonserious adverse events attributed to 
a trial drug or resulting in its discontinuation, 
and any symptoms of muscle pain or weakness or 
suggestive of hepatitis were recorded. All other 
nonserious adverse events were recorded for the 
patients in North America only. Blood pressure 
was measured at every visit with the use of an 
Omron BP760 or an equivalent local model (see 
the Methods section in Supplementary Appendix 1, 
available at NEJM.org). Blood samples were checked 
for evidence of liver or muscle injury at every visit. 
At selected visits, samples were sent for central 
analysis (including of blood lipids) and archiving.13
Primary and Secondary Outcomes
The prespecified primary outcome was the first 
major coronary event (a composite of coronary 
death, myocardial infarction, or coronary revas-
cularization). Secondary outcomes were major 
atherosclerotic events (a composite of coronary 
death, myocardial infarction, or presumed isch-
emic stroke), presumed ischemic stroke (i.e., not 
known to be hemorrhagic), and major vascular 
events (a composite of major coronary events or 
presumed ischemic stroke). Details regarding 
tertiary and other efficacy and safety assessments 
are provided in the data analysis plan in Supple-
mentary Appendix 1. All reports of possible pri-
mary and secondary outcomes, strokes, cancers, 
deaths, and serious liver or muscle events were 
centrally adjudicated by clinicians in a blinded 
fashion on the basis of prespecified definitions.13 
Adjudication was completed for more than 99.9% 
of relevant reports (see the Methods section in 
Supplementary Appendix 1).
Statistical Analysis
The data analysis plan was published on the 
trial website (www.revealtrial.org) when all the 
members of the steering committee were still un-
aware of the trial results according to group as-
signment (see the description of the data analysis 
plan in Supplementary Appendix 1).13 We as-
sumed an annual rate of major coronary events 
of 1.8% in the placebo group and determined 
that a sample size of 30,000 patients with a me-
dian follow-up of 4 years would provide the trial 
with a power of 88% at a two-tailed P value of 
less than 0.01 (and 96% power at P<0.05) to 
detect a 15% lower risk of major coronary events 
in the anacetrapib group than in the placebo 
group.13 In prespecified analyses, we used the 
log-rank method to conduct an intention-to-treat 
comparison of the time until the first event of 
interest between the patients in the anacetrapib 
group and those in the placebo group.15 With a 
stepwise approach, if the between-group differ-
ence in the primary outcome was significant at 
a two-tailed P value of less than 0.05, we would 
test for the secondary outcome of major athero-
sclerotic events; if that between-group difference 
was significant, we would test for presumed 
ischemic stroke. The components of the primary 
outcome and the remaining secondary outcome 
of major vascular events were to be assessed with-
out adjustment. The full database is held and 
analyses performed by the Clinical Trial Service 
Unit at the University of Oxford.
R esult s
Patients
From August 2011 through October 2013, a total 
of 30,449 patients underwent randomization at 
431 sites in Europe, North America, and China 
(Fig. S1 in Supplementary Appendix 1). All the 
data from one other site in the United States 
were excluded because of major protocol viola-
tions. (Details are provided in the data analysis 
plan in Supplementary Appendix 1.13) The mean 
age of the patients was 67 years; a history of coro-
nary heart disease was reported by 88% of the pa-
tients, cerebrovascular disease by 22%, peripheral-
artery disease by 8%, and diabetes mellitus by 
37% (Table 1). The cholesterol levels were well 
controlled by the atorvastatin regimen; at baseline, 
the mean LDL cholesterol level was 61 mg per 
deciliter (1.58 mmol per liter), the mean non-HDL 
cholesterol level was 92 mg per deciliter (2.38 mmol 
per liter), and the mean HDL cholesterol level 
was 40 mg per deciliter (1.03 mmol per liter).
Of the 30,449 patients, 2277 (7.5%) died dur-
ing the follow-up period; 28,096 (92.3%) survived 
until the final follow-up (including 235 [0.8%] 
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Characteristic
Anacetrapib 
(N = 15,225)
Placebo 
(N = 15,224)
All Patients 
(N = 30,449)
Age
Mean — yr 67±8 67±8 67±8
Age group — no. (%)
<65 6,634 (43.6) 6,643 (43.6) 13,277 (43.6)
65 to <70 3,380 (22.2) 3,377 (22.2) 6,757 (22.2)
≥70 5,211 (34.2) 5,204 (34.2) 10,415 (34.2)
Sex — no. (%)
Male 12,769 (83.9) 12,765 (83.8) 25,534 (83.9)
Female 2,456 (16.1) 2,459 (16.2) 4,915 (16.1)
Previous disease — no. (%)†
Coronary heart disease 13,325 (87.5) 13,354 (87.7) 26,679 (87.6)
Cerebrovascular disease 3,385 (22.2) 3,396 (22.3) 6,781 (22.3)
Peripheral-artery disease 1,229 (8.1) 1,206 (7.9) 2,435 (8.0)
Diabetes 5,654 (37.1) 5,666 (37.2) 11,320 (37.2)
Heart failure 902 (5.9) 869 (5.7) 1,771 (5.8)
Region — no. (%)
Europe 7,863 (51.6) 7,875 (51.7) 15,738 (51.7)
North America 3,048 (20.0) 3,034 (19.9) 6,082 (20.0)
China 4,314 (28.3) 4,315 (28.3) 8,629 (28.3)
Systolic blood pressure
Mean — mm Hg 131.3±18.5 131.1±18.5 131.2±18.5
Level — no. (%)
<125 mm Hg 5,678 (37.3) 5,760 (37.8) 11,438 (37.6)
125 to <140 mm Hg 4,819 (31.7) 4,740 (31.1) 9,559 (31.4)
≥140 mm Hg 4,728 (31.1) 4,724 (31.0) 9,452 (31.0)
Diastolic blood pressure
Mean — mm Hg 78.1±10.9 78.0±11.0 78.1±11.0
Level — no. (%)
<75 mm Hg 5,656 (37.1) 5,790 (38.0) 11,446 (37.6)
75 to <85 mm Hg 5,408 (35.5) 5,277 (34.7) 10,685 (35.1)
≥85 mm Hg 4,161 (27.3) 4,157 (27.3) 8,318 (27.3)
Body-mass index‡
Mean 28.6±5.0 28.6±5.1 28.6±5.1
Level — no. (%)
<25 3,447 (22.6) 3,361 (22.1) 6,808 (22.4)
25 to <30 6,949 (45.6) 6,995 (45.9) 13,944 (45.8)
≥30 4,829 (31.7) 4,868 (32.0) 9,697 (31.8)
LDL cholesterol
Mean — mg/dl 61±15 61±15 61±15
Level — no. (%)
<54 mg/dl 5,023 (33.0) 5,077 (33.3) 10,100 (33.2)
54 to <66 mg/dl 4,643 (30.5) 4,705 (30.9) 9,348 (30.7)
≥66 mg/dl 5,559 (36.5) 5,442 (35.7) 11,001 (36.1)
Table 1. Characteristics of the Patients at Baseline.*
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followed up through a review of medical records), 
33 (0.1%) withdrew consent, and 43 (0.1%) were 
lost to follow-up. The median duration of follow-
up was 4.1 years (mean, 3.8).
Adherence and Lipid Levels
Rates of adherence to the assigned trial drug and 
lipid levels were assessed approximately 2 years 
after half the patients had undergone randomiza-
tion (defined as the midpoint of the trial). Rates 
of adherence in the two groups were similar at 
the trial midpoint (89.9% for anacetrapib and 
89.7% for placebo) (Table S1 in Supplementary 
Appendix 1). There were no significant differ-
ences in the number of patients who stopped tak-
ing anacetrapib as compared with placebo before 
the end of the trial, either overall (13.5% in each 
group) or for any specific reason (Table S2 in 
Supplementary Appendix 1). Rates of adherence to 
either the atorvastatin regimen or an alternative 
statin regimen were also high (94.6% and 94.7%).
At the trial midpoint, the mean level of HDL 
cholesterol was higher by 43 mg per deciliter 
(1.12 mmol per liter) in the anacetrapib group 
than in the placebo group, a relative difference 
of 104%, and the mean level of non-HDL choles-
terol was lower by 17 mg per deciliter (0.44 mmol 
per liter), a relative difference of −18% (Table 2). 
The mean LDL cholesterol level was lower by 26 
mg per deciliter (0.68 mmol per liter) in the 
anacetrapib group than in the placebo group as 
measured on a direct assay (which underesti-
mates the LDL cholesterol level among patients 
treated with anacetrapib16), a relative difference 
of −41%, and lower by 11 mg per deciliter (0.28 
mmol per liter) as measured on beta quantifica-
tion in a randomly selected subgroup of 2000 
patients, a relative difference of −17% (Table 2). 
The mean level of apolipoprotein A1 was higher 
by 42 mg per deciliter (0.42 g per liter) in the 
anacetrapib group than in the placebo group (a 
relative difference of 36%), the mean level of apo-
Characteristic
Anacetrapib 
(N = 15,225)
Placebo 
(N = 15,224)
All Patients 
(N = 30,449)
Non-HDL cholesterol
Mean — mg/dl 92±19 92±19 92±19
Level — no. (%)
<85 mg/dl 5,642 (37.1) 5,701 (37.4) 11,343 (37.3)
85 to <101 mg/dl 4,896 (32.2) 4,853 (31.9) 9,749 (32.0)
≥101 mg/dl 4,687 (30.8) 4,670 (30.7) 9,357 (30.7)
HDL cholesterol
Mean — mg/dl 40±10 40±10 40±10
Level — no. (%)
<35 mg/dl 4,583 (30.1) 4,590 (30.1) 9,173 (30.1)
35 to <43 mg/dl 5,438 (35.7) 5,269 (34.6) 10,707 (35.2)
≥43 mg/dl 5,204 (34.2) 5,365 (35.2) 10,569 (34.7)
Glomerular filtration rate§
Mean — ml/min/1.73 m2 83±17 83±17 83±17
Level — no. (%)
<60 ml/min/1.73 m2 1,655 (10.9) 1,698 (11.2) 3,353 (11.0)
≥60 ml/min/1.73 m2 13,570 (89.1) 13,526 (88.8) 27,096 (89.0)
*  Plus–minus values are means ±SD. There were no significant differences in any of the baseline characteristics between 
the trial groups. Percentages may not total 100 because of rounding. To convert cholesterol values to millimoles per liter, 
multiply by 0.02586. HDL denotes high-density lipoprotein, and LDL low-density lipoprotein.
†  The patients could have more than one of these conditions.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  The estimated glomerular filtration rate was calculated with the use of the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation.
Table 1. (Continued.)
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lipoprotein B was lower by 12 mg per deciliter 
(0.12 g per liter, a relative difference of −18%), 
and the mean level of lipoprotein(a) was lower by 
15 nmol per liter (a relative difference of −25%).
Effects on Vascular Events
During the follow-up period, the primary out-
come occurred in significantly fewer patients in 
the anacetrapib group than in the placebo group 
(1640 of 15,225 patients [10.8%] vs. 1803 of 
15,224 patients [11.8%]; rate ratio, 0.91; 95% 
confidence interval [CI], 0.85 to 0.97; P = 0.004) 
(Fig. 1A). In a prespecified analysis, there was a 
significantly lower rate of major coronary events 
that occurred more than 1 year after randomiza-
tion in the anacetrapib group (rate ratio, 0.88; 
95% CI, 0.81 to 0.95; P = 0.001) (Fig. 1B). There 
was no significant between-group difference in 
the incidence of major coronary events during 
the first year of follow-up (rate ratio, 0.98; 95% 
CI, 0.86 to 1.11), although there was a sugges-
tion of greater risk reductions during later years 
of treatment (P = 0.03 in an exploratory test for 
trend) (Fig. 1B).
In analyses of the separate components of the 
primary outcome, the risk of myocardial infarc-
tion was significantly lower in the anacetrapib 
group than in the placebo group (rate ratio, 0.87; 
95% CI, 0.78 to 0.96; P = 0.007), but there was no 
significant between-group difference in the risk 
of coronary death (rate ratio, 0.92; 95% CI, 0.80 
to 1.06; P = 0.25), although the rate ratios were 
similar (Fig. 2). The incidence of the prespecified 
outcome of myocardial infarction or coronary 
death was significantly lower in the anacetrapib 
group (rate ratio, 0.89; 95% CI, 0.81 to 0.97; 
P = 0.008). The rate of coronary revascularization 
procedures (including surgical and percutaneous 
Lipid or Lipoprotein
Anacetrapib 
(N = 15,225)
Placebo 
(N = 15,224)
Absolute 
Difference†
Relative 
Difference
percent
Mean LDL cholesterol (mg/dl)
Direct method  38  64 −26 −41
Beta quantification‡  53  63 −11 −17
Mean non-HDL cholesterol (mg/dl)  79  96 −17 −18
Mean HDL cholesterol (mg/dl)  85  42  43 104
Mean apolipoprotein A1 (mg/dl) 160 118  42 36
Mean apolipoprotein B (mg/dl)  54  66 −12 −18
Mean triglycerides (mg/dl) 136 146 −10 −7
Mean lipoprotein(a) (nmol/liter)  43  58 −15 −25
*  Nonfasting blood samples for central laboratory assays and storage were scheduled to be taken from all surviving pa-
tients at a follow-up visit approximately 2 years after half the patients had undergone randomization (defined as the trial 
midpoint). Samples were collected a median of 716 days (interquartile range, 565 to 750) after randomization, and 
measured results were available for analysis for 93% of all the patients. In addition, lipid values — with the exclusion  
of LDL cholesterol levels as calculated by beta quantification and lipoprotein(a) levels, for which insufficient data were 
available — were imputed, as detailed in the Methods section of Supplementary Appendix 1. Imputation had no sub-
stantive effect on the absolute or proportional differences as calculated on the basis of measured values. Triglyceride 
and lipoprotein(a) levels are skewed. The median triglyceride level was 113 mg per deciliter (interquartile range, 83 to 
162) in the anacetrapib group and 123 mg per deciliter (interquartile range, 87 to 176) in the placebo group. The medi-
an level of lipoprotein(a) was 10 nmol per liter (interquartile range, 4 to 55) in the anacetrapib group and 22 nmol per 
liter (interquartile range, 9 to 87) in the placebo group. To convert cholesterol values to millimoles per liter, multiply by 
0.02586. To convert triglyceride values to millimoles per liter, multiply by 0.01129. To convert apolipoprotein values to 
grams per liter, multiply by 0.01.
†  The absolute difference is the value in the anacetrapib group minus the value in the placebo group. P<0.001 for all 
comparisons.
‡  A random subgroup of 2000 patients was selected for a comparison of two different LDL cholesterol assays. LDL cho-
lesterol was measured by beta quantification in samples obtained 2 years after randomization, and the results were 
available for 92% of the selected patients. For comparison, the mean LDL cholesterol level, as measured by the direct 
method in the same samples, was 39 mg per deciliter in the anacetrapib group versus 64 mg per deciliter in the placebo 
group, for an absolute difference of −26 mg per deciliter and a relative difference of −40%.
Table 2. Effects of Anacetrapib on Blood Lipids and Lipoproteins at Trial Midpoint.*
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interventions) was significantly lower in the 
anacetrapib group than in the placebo group 
(rate ratio, 0.90; 95% CI, 0.83 to 0.97; P = 0.01), 
with the effect appearing to be largely restricted 
to urgent procedures (rate ratio, 0.80; 95% CI, 
0.70 to 0.90; P<0.001) rather than routine proce-
dures (rate ratio, 0.97; 95% CI, 0.87 to 1.07; 
P = 0.50) (Table S3 in Supplementary Appendix 1).
Figure 1. First Major Coronary Event during Follow-up.
Panel A shows a Kaplan–Meier plot of the first major coronary event (a composite of coronary death, myocardial infarc-
tion, or coronary revascularization) during follow-up. The numbers of patients at risk at the start of each year of follow-up 
are shown, along with the mean (±SE) absolute differences in incidence rates between the patients in the anacetrapib 
group and those in the placebo group. The inset graph shows the same data on an expanded y axis. Panel B shows rate 
ratios for the first major coronary event among the patients in the anacetrapib group versus those in the placebo group, 
according to the period of follow-up. The numbers at risk decline with each year of follow-up because of censoring, so the 
percentages are the number of events as a proportion of the number at risk. For each year of follow-up, rate ratios are 
plotted as squares, with the size of each square proportional to the amount of statistical information that was available; 
the horizontal lines represent 95% confidence intervals (CIs), and the dashed vertical line indicates the overall rate ratio 
for the effect of anacetrapib on the first major coronary event. For prespecified composite periods of follow-up (indicated 
in bold text), rate ratios and their corresponding 95% confidence intervals are represented by diamonds, and P values 
are shown. Squares or diamonds to the left of the solid vertical line indicate benefit with anacetrapib, but the compari-
son is significant (P<0.05) only if the horizontal line or diamond does not overlap with the solid vertical line.
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The between-group difference in the rate of 
the secondary composite outcome of major ath-
erosclerotic events (i.e., myocardial infarction, 
coronary death, or presumed ischemic stroke) was 
not significant (rate ratio, 0.93; 95% CI, 0.86 to 
1.00; P = 0.052) (Fig. 2). Consequently, the effect 
of anacetrapib on presumed ischemic stroke 
(rate ratio, 0.99; 95% CI, 0.87 to 1.12) was not 
formally tested. However, there was a significant 
reduction in the secondary outcome of major 
vascular events (i.e., major coronary event or 
presumed ischemic stroke) (rate ratio, 0.93; 95% 
CI, 0.88 to 0.99; P = 0.02), and the results were 
consistent for the components of this end point. 
There were no apparent effects on hemorrhagic 
stroke, on noncoronary revascularization proce-
dures, or on hospitalization for heart failure 
(Table S3 in Supplementary Appendix 1).
The proportional effects of anacetrapib on 
major coronary events were compared across 23 
prespecified subgroup categories (Fig. S2 in Sup-
plementary Appendix 1). There was no significant 
evidence of differential proportional effects within 
any of these categories, with only one category 
(the use of an angiotensin-converting–enzyme 
inhibitor or angiotensin-receptor blocker at base-
line vs. no such use) that resulted in a nominal 
P value for heterogeneity of less than 0.05, a dif-
ference that was not significant after adjustment 
for multiple comparisons.
 Effects on Death, Cancer, and Other Adverse 
Events
There were no significant effects of anacetrapib 
on rates of death from cardiovascular causes 
(3.4% with anacetrapib vs. 3.7% with placebo, 
P = 0.17), death from all noncardiovascular causes 
(4.0% vs. 3.9%, P = 0.77), or death from all causes 
combined (7.4% vs. 7.6%, P = 0.46) (Fig. S3 in 
Supplementary Appendix 1). There were also no 
significant effects on the incidence of fatal or 
nonfatal cancer, either overall (6.4% vs. 6.3%, 
P = 0.71) or at any prespecified site (Fig. S4 in 
Supplementary Appendix 1). There were no sig-
nificant excesses in any major category of serious 
or nonserious adverse events (Table S4 in Supple-
mentary Appendix 1). Detailed tabulations of 
adverse events are provided in Supplementary 
Appendix 2, available at NEJM.org.
Among the patients without diabetes mellitus 
Figure 2. Primary and Secondary Outcomes.
The primary outcome was a major coronary event (a composite of coronary death, myocardial infarction [MI], or 
coronary revascularization). Secondary outcomes were a major atherosclerotic event (coronary death, MI, or pre-
sumed ischemic stroke), presumed ischemic stroke (i.e., not known to be hemorrhagic), and a major vascular event 
(major coronary event or presumed ischemic stroke). The composite of coronary death or MI was a prespecified ter-
tiary outcome. A single patient may have had multiple events and therefore may contribute information to more than 
one row. The size of each square for rate ratio is proportional to the amount of statistical information that was avail-
able, the horizontal lines represent 95% confidence intervals, and the dashed vertical line indicates the overall rate 
ratio for the effect of anacetrapib on the first major coronary event. For composite outcomes, rate ratios and their 
corresponding 95% confidence intervals are represented by bold text and diamonds. In accordance with the data 
analysis plan, since the outcome of a major atherosclerotic event did not reach significance, there was no hypothe-
sis testing for presumed ischemic stroke, so no P value is shown (as indicated by NA for not applicable).
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at baseline, the incidence of new-onset diabetes 
mellitus was lower in the anacetrapib group than 
in the placebo group (5.3% vs. 6.0%; rate ratio, 
0.89; 95% CI, 0.79 to 1.00; P = 0.0496), and the 
mean glycated hemoglobin level was 0.03 per-
centage point lower (Table S5 in Supplementary 
Appendix 1). However, there was no apparent ef-
fect on glycated hemoglobin level among the pa-
tients with diabetes at baseline.
Patients in the anacetrapib group had slightly 
higher blood-pressure levels than did those in 
the placebo group, with higher levels of systolic 
blood pressure (by 0.7 mm Hg) and diastolic 
blood pressure (by 0.3 mm Hg) at the final visit. 
However, there was no significant difference in 
the rates of serious adverse events attributed to 
hypertension (1.0% in the anacetrapib group vs. 
0.9% in the placebo group) (Table S6 in Supple-
mentary Appendix 1). By the end of the trial, an 
estimated glomerular filtration rate (GFR) of 
less than 60 ml per minute per 1.73 m2 of body-
surface area had developed in more patients in 
the anacetrapib group than in the placebo group 
(11.5% vs. 10.6%, P = 0.04), but there were no 
significant between-group differences in the de-
velopment of albuminuria. In exploratory analy-
ses, there were no significant between-group 
differences in the proportions of patients with a 
40% decline in the estimated GFR between the 
baseline visit and the final visit or with serious 
adverse events attributed to renal failure.
Regarding any effects on muscles, there were 
slightly higher rates of moderate elevations in 
creatine kinase (10 to 40 times the upper limit 
of the normal range) in the anacetrapib group 
than in the placebo group but slightly lower 
rates of more severe elevations (>40 times the 
upper limit of the normal range) (Table S7 in 
Supplementary Appendix 1). There was no evidence 
of adverse effects associated with anacetrapib on 
macular degeneration (in contrast to previous ge-
netic studies17), liver disorders, or mood or cogni-
tive function (Tables S6 and S7 in Supplementary 
Appendix 1).18,19
Discussion
In this randomized trial, we found that the ad-
dition of the CETP inhibitor anacetrapib at a 
dose of 100 mg daily to intensive statin therapy 
for approximately 4 years resulted in a lower 
incidence of major coronary events than the ad-
dition of placebo among patients with preexist-
ing atherosclerotic vascular disease, despite very 
well-controlled baseline LDL cholesterol levels 
(mean, 61 mg per deciliter [1.58 mmol per liter]). 
The proportional risk reductions appeared to be 
larger with more prolonged follow-up.
Our trial has a number of strengths that facili-
tated assessments of both efficacy and safety, 
including recruitment of a large number of pa-
tients, high treatment adherence, follow-up for a 
median of more than 4 years, and a large num-
ber of clinical outcomes. Our results contrast 
with those reported from clinical outcome trials 
of other CETP inhibitors. The Investigation of 
Lipid Level Management to Understand its Impact 
in Atherosclerotic Events (ILLUMINATE) trial was 
terminated early because of excess risks of car-
diac events and death with torcetrapib, findings 
that have been attributed to off-target drug ef-
fects.8,20,21 Subsequently, the Effects of Dalcetrapib 
in Patients with a Recent Acute Coronary Syn-
drome (Dal-OUTCOMES) trial and the Assessment 
of Clinical Effects of Cholesteryl Ester Transfer 
Protein Inhibition with Evacetrapib in Patients at 
a High Risk for Vascular Outcomes (ACCELERATE) 
were both stopped early after approximately 
2 years of treatment because of an apparent lack of 
efficacy.9,10 Dalcetrapib is a relatively weak CETP 
inhibitor that does not lower LDL cholesterol at the 
dose tested in Dal-OUTCOMES,9 whereas evace-
trapib has effects on blood lipid levels similar to 
those of anacetrapib.10 However, ACCELERATE 
differed from our trial in several ways. In par-
ticular, it involved fewer patients (12,092 vs. 
30,449), a shorter treatment period (median, 26 
months vs. 50 months), and fewer primary car-
diovascular outcomes (1555 vs. 3443). Our trial 
results suggest that the full effects of anacetra-
pib may take at least a year of treatment to 
emerge. A similar pattern has been observed in 
randomized trials of other lipid-lowering drugs.2-4 
Consequently, the follow-up duration of just over 
2 years in ACCELERATE may have been too short 
to allow an effect on vascular events to emerge.
It is not possible to determine the mechanism 
by which anacetrapib reduced the risk of major 
coronary events in this trial. On the basis of 
evidence from trials of statin therapy,2 the lower 
level of non-HDL cholesterol (by 17 mg per deci-
liter) in the anacetrapib group than in the pla-
cebo group as seen in our trial would be antici-
pated to result in a 10% relative reduction in the 
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risk of coronary death or myocardial infarction 
(Fig. S5 in Supplementary Appendix 1), a finding 
that is entirely consistent with the 11% reduction 
that we observed. This result reduces the likeli-
hood that other actions of anacetrapib played a 
major role in modifying the risk of coronary 
events. In particular, the higher mean level of 
HDL cholesterol in the anacetrapib group (by 43 
mg per deciliter) does not appear to have had as 
large an effect on coronary events as would be 
anticipated on the basis of observational stud-
ies.22 Analyses of genetic variants in CETP also 
indicate that differences in coronary risk are 
related largely to differences in LDL cholesterol 
levels.23 LDL cholesterol levels were particularly 
well controlled among the patients throughout 
our trial. The beneficial effects of anacetrapib 
may be greater among patients with higher base-
line LDL cholesterol levels, in whom the absolute 
reductions in LDL cholesterol levels may be 
greater.
During a median of 4 years of follow-up, 
anacetrapib treatment was not associated with 
any of the previously hypothesized adverse ef-
fects of very low levels of cholesterol (e.g., re-
duced cognitive function, increased cancer inci-
dence, or nonvascular death).24 Unlike previous 
and much smaller studies of anacetrapib,11,25 our 
trial showed a slightly higher level of systolic 
blood pressure (0.7 mm Hg) in the anacetrapib 
group than in the placebo group, a difference 
that was similar in magnitude to effects re-
ported for dalcetrapib and evacetrapib but much 
smaller than the increase of 5 mm Hg seen with 
torcetrapib.8-10 In addition, the risk of the devel-
opment of an estimated GFR of less than 60 ml 
per minute per 1.73 m2 was slightly higher. As has 
been observed with torcetrapib26 and evacetrapib27 
(but not with dalcetrapib9), anacetrapib was as-
sociated with a lower incidence of new-onset 
diabetes, which contrasts with the small in-
crease seen with statins28 or, to a greater extent, 
niacin.5
Our trial has certain limitations. LDL choles-
terol levels were very well controlled, and the 
median follow-up was only 4 years, so our find-
ings may not be generalizable to patients with 
longer-term use of anacetrapib and those with 
higher LDL cholesterol levels. Anacetrapib contin-
ues to accumulate in adipose tissue with pro-
longed administration,29 and although plasma 
levels fall substantially after cessation of treat-
ment, levels in adipose tissue decline only mini-
mally after 1 year.29,30 No substantial safety issues 
were identified during the trial, but follow-up 
for clinical outcomes in trial patients is being 
continued for at least an additional 2 years after 
the end of the treatment period to assess longer-
term safety, as well as efficacy.
In conclusion, we found that the addition of 
the CETP inhibitor anacetrapib to intensive statin 
treatment in patients with atherosclerotic vascu-
lar disease resulted in a significantly lower inci-
dence of major coronary events than the addition 
of placebo during 4 years of treatment.
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